Jun. 9 at 6:06 PM
$URGN 10-year analyst consensus revenue estimates versus the 10-year revenue forecast prepared by
$DCPH management provided to Ono when Ono opted to acquire DCPH for an enterprise value of
$2.1B
Analysts project URGN to generate roughly
$2.7B in product revenues over the next 5 years. This is roughly 50% more than DCPH projected when acquired for
$2.1B (though 10year revenue forecasts are closer).
As we recall, at the time the acquisition was announced in Jun 2024, DCPH had filed or was about to file for Vimseltinib approval. Vimseltinib was approved by the FDA on 2/14/25.
We're curious if investors believe DCPH is a good peer/comp to guesstimate a hypothetical URGN M&A exit valuation. We'd think, all other things being equal, URGN would get a tad more (though DCPH's gross margins were 5% higher).
Using DCPH as a peer (which is risky), we'd guess URGN would exit for between
$2.3 &
$2.6B in EV (not market cap). Pushback?
This is not investment advice. This is speculation.
$XBI $IBB
